SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation

Biotech SG&A: Halozyme vs. Dynavax Efficiency

__timestamp	Dynavax Technologies Corporation	Halozyme Therapeutics, Inc.
Wednesday, January 1, 2014	17763000	35942000
Thursday, January 1, 2015	22180000	40028000
Friday, January 1, 2016	37257000	45853000
Sunday, January 1, 2017	27367000	53816000
Monday, January 1, 2018	64770000	60804000
Tuesday, January 1, 2019	74986000	77252000
Wednesday, January 1, 2020	79256000	45736000
Friday, January 1, 2021	100156000	50323000
Saturday, January 1, 2022	131408000	143526000
Sunday, January 1, 2023	152946000	149182000
Monday, January 1, 2024		154335000

Unlocking the unknown

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, both companies have shown significant growth in their SG&A expenses, reflecting their expanding operations and strategic investments.

Key Insights

Dynavax Technologies: Starting with a modest 18% of Halozyme's expenses in 2014, Dynavax's SG&A expenses surged by over 760% by 2023, indicating aggressive scaling and market penetration efforts.
Halozyme Therapeutics: While maintaining a steady growth trajectory, Halozyme's expenses increased by approximately 315% over the same period, showcasing a balanced approach to expansion.

This data highlights the dynamic strategies employed by these biotech firms in navigating the complexities of the industry.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Selling, General, and Administrative Costs: Catalent, Inc. vs Halozyme Therapeutics, Inc.

Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?

Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.

SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc

Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends

Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights

Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.

Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation

Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation

Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared

Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Dynavax Technologies Corporation

Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation